4AVV

Structure of CPHPC bound to Serum Amyloid P Component

4AVV の概要

• エントリーDOI: 10.2210/pdb4avv/pdb
• 関連するPDBエントリー: 1GYK 1LGN 1SAC 2A3W 2A3X 2A3Y 2W08 4AVS 4AVT 4AYU
• 分子名称: SERUM AMYLOID P-COMPONENT, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, N-acetyl-alpha-neuraminic acid-(2-6)-beta-D-galactopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-2)-alpha-D-mannopyranose-(1-3)-[N-acetyl-alpha-neuraminic acid-(2-6)-beta-D-galactopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-2)-alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, ... (9 entities in total)
• 機能のキーワード: sugar binding protein, lectin, metal-binding
• 由来する生物種: HOMO SAPIENS (HUMAN)
• タンパク質・核酸の鎖数: 5
• 化学式量合計: 126142.17

構造登録者

Kolstoe, S.E.,Jenvey, M.C.,Wood, S.P. (登録日: 2012-05-29, 公開日: 2013-06-19, 最終更新日: 2024-11-13)

主引用文献

Kolstoe, S.E.,Jenvey, M.C.,Purvis, A.,Light, M.E.,Thompson, D.,Hughes, P.,Pepys, M.B.,Wood, S.P.
Interaction of Serum Amyloid P Component with Hexanoyl Bis(D-Proline) (Cphpc)
Acta Crystallogr.,Sect.D, 70:2232-, 2014

PubMed Abstract: Under physiological conditions, the pentameric human plasma protein serum amyloid P component (SAP) binds hexanoyl bis(D-proline) (R-1-{6-[R-2-carboxy-pyrrolidin-1-yl]-6-oxo-hexanoyl}pyrrolidine-2-carboxylic acid; CPHPC) through its D-proline head groups in a calcium-dependent interaction. Cooperative effects in binding lead to a substantial enhancement of affinity. Five molecules of the bivalent ligand cross-link and stabilize pairs of SAP molecules, forming a decameric complex that is rapidly cleared from the circulation by the liver. Here, it is reported that X-ray analysis of the SAP complex with CPHPC and cadmium ions provides higher resolution detail of the interaction than is observed with calcium ions. Conformational isomers of CPHPC observed in solution by HPLC and by X-ray analysis are compared with the protein-bound form. These are discussed in relation to the development of CPHPC to provide SAP depletion for the treatment of amyloidosis and other indications.

PubMed: 25084341
DOI: 10.1107/S1399004714013455

実験手法

X-RAY DIFFRACTION (1.6 Å)